Article metrics
PDF
Other content recommended for you
- What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
- Why using Avastin for eye disease is so difficult
- Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
- Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
- Implications of “not me” drugs for health systems: lessons from age related macular degeneration
- Why have UK doctors been deterred from prescribing Avastin?